Lyell Immunopharma (NASDAQ:LYEL) Announces Earnings Results

Lyell Immunopharma (NASDAQ:LYEL) posted its quarterly earnings results on Thursday. The company reported ($1.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.02) by $0.10, reports. Lyell Immunopharma had a negative net margin of 920,285.25% and a negative return on equity of 87.60%. The company had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.01 million.

Lyell Immunopharma Price Performance

Shares of LYEL stock traded up $0.50 during trading hours on Friday, reaching $14.71. 110,955 shares of the company were exchanged, compared to its average volume of 170,417. The company has a market cap of $360.39 million, a price-to-earnings ratio of -1.15 and a beta of -0.04. The stock’s fifty day moving average is $13.44 and its two-hundred day moving average is $19.01. Lyell Immunopharma has a fifty-two week low of $9.28 and a fifty-two week high of $45.00.

Institutional Investors Weigh In On Lyell Immunopharma

A number of institutional investors have recently made changes to their positions in LYEL. AQR Capital Management LLC lifted its stake in Lyell Immunopharma by 773.5% in the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock valued at $94,000 after buying an additional 154,327 shares during the period. Marshall Wace LLP bought a new position in Lyell Immunopharma during the second quarter worth about $94,000. Bridgeway Capital Management LLC acquired a new position in shares of Lyell Immunopharma during the 2nd quarter worth about $159,000. Walleye Capital LLC bought a new stake in shares of Lyell Immunopharma in the 2nd quarter valued at about $258,000. Finally, ExodusPoint Capital Management LP bought a new stake in shares of Lyell Immunopharma in the 4th quarter valued at about $262,000. 66.05% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts recently commented on LYEL shares. HC Wainwright reaffirmed a “buy” rating and issued a $45.00 target price on shares of Lyell Immunopharma in a research report on Tuesday, June 9th. Wall Street Zen raised shares of Lyell Immunopharma from a “sell” rating to a “hold” rating in a report on Sunday, May 10th. Citigroup reissued a “market outperform” rating on shares of Lyell Immunopharma in a research note on Tuesday, June 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Friday, July 17th. Finally, Stifel Nicolaus initiated coverage on Lyell Immunopharma in a research report on Thursday. They issued a “buy” rating and a $36.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Lyell Immunopharma has a consensus rating of “Moderate Buy” and an average target price of $42.00.

Lyell Immunopharma Company Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.